Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

More or Less is produced in partnership with the Open University. Presenter: Tim Harford Reporter: Lizzy McNeill Producer: ...

This segment is sponsored by Eli Lilly and Company.Social media is flooded with advertisments for popular obestiy medications ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

For many years, health experts have been concerned about "food deserts," places where residents lack good nutritional options ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

To improve access to care, many professional organizations have advocated for classifying obesity as a disease. However, the ...

Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...